Quantum Surgical Acquires NeuWave Medical, Expanding Robotic Precision in Cancer Treatment
Berlin, Germany – In a move poised to reshape the landscape of minimally invasive cancer treatment, Quantum Surgical has acquired NeuWave Medical. This strategic acquisition, announced on February 26, 2026, aims to broaden access to robotic-assisted tumor ablation therapies, ultimately striving to reduce cancer mortality rates globally. Both companies will now operate as subsidiaries under the newly formed Precision IO Group, led by CEO Kurt Azarbarzin.
The convergence of Quantum Surgical’s innovative robotic platform, Epione, and NeuWave Medical’s established microwave ablation technology represents a significant step forward in interventional oncology. This collaboration promises to enhance the precision, efficiency, and accessibility of treatments for a range of cancers, particularly those affecting the liver, lung, and musculoskeletal system. The acquisition underscores a growing trend towards robotic assistance in complex medical procedures, offering the potential for improved patient outcomes and reduced recovery times.
Epione and NeuWave: Complementary Technologies
Quantum Surgical has pioneered the Epione robotic platform, designed for early-stage tumor interventions. The system allows physicians to perform percutaneous tumor ablations – a minimally invasive technique where needles are inserted through the skin to destroy cancerous tissue – with enhanced accuracy and control. According to the company, Epione streamlines the ablation procedure workflow, addressing limitations and complexities that have historically hindered wider adoption of percutaneous ablation as a first-line cancer treatment. The platform received CE marking for abdominal, chest, and musculoskeletal indications, and FDA clearance for abdominal ablation, demonstrating its regulatory acceptance in key markets.
NeuWave Medical, meanwhile, is a leading provider of microwave ablation technology used in percutaneous procedures. Their technology is currently utilized in approximately 70% of cancer centers across the United States, highlighting its widespread acceptance and clinical utility. Microwave ablation uses heat generated by microwaves to destroy tumor cells, offering a targeted and effective treatment option for patients who may not be suitable candidates for surgical resection. The combination of NeuWave’s established technology with Epione’s robotic precision is expected to create a synergistic effect, further optimizing treatment outcomes.
Democratizing Procedural Understand-How and Expanding Access
Bertin Nahum, president and co-founder of Quantum Surgical, emphasized the company’s commitment to expanding access to high-quality cancer care. “At Quantum Surgical, we are committed to democratising procedural know-how through robotics and expanding high-quality cancer care for patients,” Nahum stated. “Acquiring NeuWave Medical is a natural and strategic step in that mission.” He further noted that innovation remains the company’s guiding principle, and the collaboration with NeuWave’s team will drive further advancements in interventional oncology.
Leah Kissling, president of NeuWave Medical, echoed this sentiment, expressing pride in joining the Quantum Surgical team. “We’re proud to join the Quantum Surgical team and continue supporting physicians in their mission to treat cancer patients,” Kissling said. “We look forward to combining our capabilities with Quantum Surgical to drive innovation and aid transform the future of cancer care.”
Remote Intervention and Global Collaboration
Precision IO Group is actively developing remote intervention projects leveraging the capabilities of the Epione platform. This innovative approach aims to facilitate real-time global collaboration among physicians, allowing experts to provide guidance on trajectory planning and results assessment remotely. This has the potential to significantly improve access to specialized care, particularly for patients in underserved areas or those lacking access to experienced interventional oncologists. Remote interventions could enable precise, minimally invasive procedures to be performed with the support of global expertise, regardless of geographical limitations.
The potential benefits of remote intervention extend beyond increased access to care. It also offers opportunities for enhanced training and mentorship, allowing less experienced physicians to learn from leading experts in the field. This collaborative approach could lead to a more standardized and consistent level of care for cancer patients worldwide.
The Growing Field of Tumor Ablation
Tumor ablation is increasingly recognized as a valuable treatment modality for a variety of cancers, particularly those affecting the liver, lung, kidney, and bone. According to the American Cancer Society, more than 41,000 new cases of liver cancer are diagnosed in the United States each year. While surgical resection offers the best outcomes for patients who are eligible, up to 75% of individuals with liver cancer are not suitable candidates due to multiple tumors or compromised liver function. Percutaneous ablation provides a less invasive alternative for these patients, offering the potential for effective tumor control and improved quality of life.
The FDA has approved the Epione system for the treatment of all abdominal cancers, expanding its potential applications beyond liver cancer. The system has already been used to treat over 1,400 patients in the United States and Europe, demonstrating its clinical viability and safety. The increasing adoption of robotic-assisted ablation technologies reflects a broader trend towards minimally invasive surgical techniques, driven by the desire to reduce patient trauma, shorten recovery times, and improve overall outcomes.
Looking Ahead
The acquisition of NeuWave Medical by Quantum Surgical marks a pivotal moment in the evolution of robotic-assisted cancer treatment. By combining their respective strengths, the two companies are poised to accelerate innovation and expand access to cutting-edge therapies for patients worldwide. Precision IO Group’s focus on remote intervention further underscores the potential for technology to overcome geographical barriers and democratize access to specialized medical expertise.
The next step for Precision IO Group will be to continue refining the Epione platform and expanding its clinical applications. Further research and development efforts will likely focus on improving the precision and efficiency of ablation procedures, as well as exploring new indications for the technology. The company is also expected to pursue additional regulatory approvals in key markets, paving the way for wider adoption of its innovative solutions.
What are your thoughts on the increasing role of robotics in cancer treatment? Share your comments below, and let’s continue the conversation.